Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in pulmonary tuberculosis
NCT03941496Phase 2Withdrawn
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in Tuberculosis (TB). Primary endpoints: Overall incidence of all investigational product-related adverse events at 2 years, Overall severity of all investigational product-related adverse events at 4 months and 1 more. Planned start Oct 2022; status: withdrawn.
02
Drugs
azacitidine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03941496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941496.